Xbrane Biopharma AB (publ) (XBRANE.ST)
SEK 0.16
(-3.53%)
SEK 0.16
(-3.53%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 35.38 Million SEK | -66.0% |
| 2022 | 41.04 Million SEK | 6100.29% |
| 2021 | -684 Thousand SEK | -127.91% |
| 2020 | 2.45 Million SEK | 113.87% |
| 2019 | -17.67 Million SEK | -118.21% |
| 2018 | 97.04 Million SEK | 1863.7% |
| 2017 | 4.94 Million SEK | 219.63% |
| 2016 | -4.13 Million SEK | -2435.8% |
| 2015 | 176.85 Thousand SEK | -6.74% |
| 2014 | 189.62 Thousand SEK | 108.48% |
| 2013 | 90.95 Thousand SEK | 135.78% |
| 2012 | -254.17 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 217 Thousand SEK | -94.88% |
| 2024 Q2 | 65.38 Million SEK | 30031.34% |
| 2024 Q3 | 44.65 Million SEK | -31.71% |
| 2023 Q3 | 4.15 Million SEK | -63.79% |
| 2023 Q4 | 4.23 Million SEK | 2.05% |
| 2023 Q2 | 11.46 Million SEK | -24.64% |
| 2023 FY | 13.95 Million SEK | -66.0% |
| 2023 Q1 | 15.21 Million SEK | -8.09% |
| 2022 Q2 | 15.63 Million SEK | 117.4% |
| 2022 Q4 | 16.55 Million SEK | 18.82% |
| 2022 FY | 41.04 Million SEK | 6100.29% |
| 2022 Q1 | 7.19 Million SEK | -5.9% |
| 2022 Q3 | 13.93 Million SEK | -10.85% |
| 2021 Q2 | -34 Thousand SEK | -126.36% |
| 2021 Q1 | 129 Thousand SEK | -98.11% |
| 2021 FY | -684 Thousand SEK | -127.91% |
| 2021 Q4 | 7.64 Million SEK | 946.18% |
| 2021 Q3 | -903 Thousand SEK | -2555.88% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 FY | 2.45 Million SEK | 113.87% |
| 2020 Q4 | 6.82 Million SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 100.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q4 | -17.67 Million SEK | 0.0% |
| 2019 FY | -17.67 Million SEK | -118.21% |
| 2019 Q1 | - SEK | -100.0% |
| 2018 Q3 | 512 Thousand SEK | -36.48% |
| 2018 Q2 | 806 Thousand SEK | -60.1% |
| 2018 Q4 | 93.7 Million SEK | 18202.34% |
| 2018 Q1 | 2.02 Million SEK | -11.34% |
| 2018 FY | 97.04 Million SEK | 1863.7% |
| 2017 Q4 | 2.27 Million SEK | 1049.39% |
| 2017 Q3 | -239.97 Thousand SEK | -117.62% |
| 2017 Q2 | 1.36 Million SEK | -69.76% |
| 2017 FY | 4.94 Million SEK | 219.63% |
| 2017 Q1 | 4.5 Million SEK | 183.43% |
| 2016 Q2 | 572.99 Thousand SEK | -24.47% |
| 2016 Q3 | -65.76 Thousand SEK | -111.48% |
| 2016 Q1 | 758.67 Thousand SEK | 673.59% |
| 2016 Q4 | -5.39 Million SEK | -8106.26% |
| 2016 FY | -4.13 Million SEK | -2435.8% |
| 2015 Q2 | 73.8 Thousand SEK | -30.54% |
| 2015 Q1 | 106.24 Thousand SEK | 107.65% |
| 2015 FY | 176.85 Thousand SEK | -6.74% |
| 2015 Q4 | -132.26 Thousand SEK | -201.75% |
| 2015 Q3 | 129.98 Thousand SEK | 76.13% |
| 2014 Q3 | -167.53 Thousand SEK | 0.0% |
| 2014 Q4 | -1.38 Million SEK | -729.07% |
| 2014 FY | 189.62 Thousand SEK | 108.48% |
| 2013 FY | 90.95 Thousand SEK | 135.78% |
| 2012 FY | -254.17 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 122.023% |
| Ziccum AB (publ) | -23.28 Million SEK | 251.971% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 89.782% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 15.313% |
| Mendus AB (publ) | 28.48 Million SEK | -24.225% |
| Genovis AB (publ.) | 54 Million SEK | 34.468% |
| Intervacc AB (publ) | -13.79 Million SEK | 356.546% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -1530.032% |
| Active Biotech AB (publ) | -1.67 Million SEK | 2212.716% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | -255.194% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | -31.941% |
| Aptahem AB (publ) | 2.63 Million SEK | -1245.22% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 1134.434% |
| Kancera AB (publ) | -1.96 Million SEK | 1900.916% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -45858.442% |
| Fluicell AB (publ) | 1.73 Million SEK | -1936.133% |
| Saniona AB (publ) | 11.78 Million SEK | -200.382% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 791.577% |
| Biovica International AB (publ) | 6.87 Million SEK | -414.585% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 251.991% |
| AcouSort AB (publ) | 8.38 Million SEK | -321.838% |
| Xintela AB (publ) | 78 Thousand SEK | -45269.231% |
| Abliva AB (publ) | -35.66 Million SEK | 199.229% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 124.09% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -1160.705% |
| OncoZenge AB (publ) | 3000.00 SEK | -1179500.0% |
| Amniotics AB (publ) | -1.93 Million SEK | 1933.575% |
| 2cureX AB (publ) | -37.48 Million SEK | 194.401% |
| CombiGene AB (publ) | -21.29 Million SEK | 266.214% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 8465.957% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 96.868% |
| Camurus AB (publ) | 1.58 Billion SEK | 97.761% |
| Corline Biomedical AB | 28.38 Million SEK | -24.693% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 128.833% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 202.827% |
| I-Tech AB | 27.56 Million SEK | -28.376% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 50.123% |
| Cyxone AB (publ) | 2.61 Million SEK | -1255.343% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | -939.906% |
| Biosergen AB | -456 Thousand SEK | 7860.526% |
| Cantargia AB (publ) | -3.45 Million SEK | 1125.442% |
| NextCell Pharma AB | -43.74 Million SEK | 180.89% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 484.903% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | -215.449% |
| Nanologica AB (publ) | -76 Thousand SEK | 46663.158% |
| SynAct Pharma AB | -778 Thousand SEK | 4648.586% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 18435.751% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 373.859% |
| Lipum AB (publ) | 53 Thousand SEK | -66669.811% |
| BioInvent International AB (publ) | 71.46 Million SEK | 50.479% |
| Alzinova AB (publ) | 19.87 Million SEK | -78.062% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 2.51% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -2318.832% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 236020.0% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -2034.379% |
| Simris Alg AB (publ) | 2 Million SEK | -1663.229% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 1088.492% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 3473.499% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -1029.524% |